Shrinks In Sneakers

Tag: depression

  • 🧠 New Insights into Depression: How the Brain’s “Negativity Bias” Shapes Our Perceptions

    🧠 New Insights into Depression: How the Brain’s “Negativity Bias” Shapes Our Perceptions

    Did you know that in depression, the brain’s wiring can actually amplify negative experiences? Recent research from the Institut Pasteur and collaborators explored this phenomenon, finding that depression alters specific neurons in the amygdala. These changes can reduce activity in neurons that process positive stimuli while overactivating those that process negative stimuli. This “negativity bias” means people with depression often perceive even neutral events through a negative lens.

    In studies with mouse models of depression, activating neurons responsible for positive perceptions helped reduce depressive behaviors. This groundbreaking discovery could pave the way for new treatments aimed at rebalancing these circuits, especially for people who don’t respond to conventional therapies.

    By understanding depression’s effects on the amygdala, researchers hope to develop more targeted and effective therapies for those resistant to current treatments. This is a step toward a more personalized approach to mental health.

    link to the article: https://pmc.ncbi.nlm.nih.gov/articles/PMC10963437/

  • New Strategies to Slow Cognitive Loss in Major Depression

    New Strategies to Slow Cognitive Loss in Major Depression

    📢 New Publication Alert in JAMA Psychiatry 🧠📄

    Today’s issue of JAMA Psychiatry highlights an important breakthrough study titled: “Slowing cognitive decline in major depressive disorder and mild cognitive impairment: A randomized controlled trial.”

    This publication reveals the primary findings from the PACt-MD study (Prevention of Alzheimer’s dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression). This large-scale RCT examined whether combining cognitive remediation therapy (CRT) with transcranial direct current stimulation (tDCS) could effectively slow cognitive decline in individuals with both mild cognitive impairment (MCI) and major depressive disorder (MDD).

    Key Findings:

    • The combination of CRT and tDCS showed promising effects in decelerating cognitive decline in patients with MCI and MDD.
    • Improved cognitive outcomes were observed in specific areas such as memory, executive function, and attention compared to control groups.

    Why This Matters: Cognitive impairment is a critical concern in both MCI and MDD, often leading to functional decline and increased dementia risk. This study provides valuable insights into non-pharmacological approaches to mitigate cognitive deterioration in high-risk populations.

    🔍 Stay tuned for more on the methodology and detailed results. This could open doors to novel, accessible interventions for those at risk of Alzheimer’s and cognitive impairment.

    Artile lonk: https://pubmed.ncbi.nlm.nih.gov/32568198/

  • Cobenfy: New Insights into Efficacy and Comparative Impact on Schizophrenia Symptoms

    Cobenfy: New Insights into Efficacy and Comparative Impact on Schizophrenia Symptoms

    Overall Efficacy

    • Effect Size: Cobenfy’s overall efficacy on the Positive and Negative Syndrome Scale (PANSS) stands at an effect size of 0.6, which is higher than many established antipsychotics (typically 0.3-0.5). However, clozapine still leads as the gold standard, with effect sizes ranging from 0.76 to 1.0.
    • NNT (Number Needed to Treat): The estimated NNT for Cobenfy is around 4, placing it in the mid-range among antipsychotics, where NNTs often range from 3 to 10.

    Negative Symptom Impact

    • Cobenfy shows a notable efficacy in reducing negative symptoms. It achieves an impressive effect size of 1.18for this symptom domain, which is uncommon among antipsychotics. This improvement in negative symptoms appears to be independent of reductions in positive symptoms, a distinct advantage over traditional agents.
    • The NNT for negative symptoms specifically is around 2, highlighting Cobenfy’s potential as a robust option for patients struggling with these challenging symptoms.

    Onset of Action

    • Rapid Onset: Cobenfy begins to show statistically significant improvements by week 3.
    • Peak Effect: Maximal symptom improvement is typically observed by week 5.

    Conclusion
    Cobenfy offers strong efficacy in schizophrenia, with unique advantages for negative symptoms. While clozapine remains unmatched in treatment-resistant cases, Cobenfy provides a promising option, especially for patients with significant negative symptoms.

  • Lurasidone vs. Quetiapine: Which Will Emerge as the Top Choice for Bipolar Depression?

    Lurasidone vs. Quetiapine: Which Will Emerge as the Top Choice for Bipolar Depression?

    Bipolar depression is a challenging and common condition, with limited options for effective medication management. Finding the best treatment can be tough, especially given the lack of high-quality head-to-head comparisons in the literature. Two frequently prescribed medications for bipolar depression, quetiapine and lurasidone, are both solid options—but is one truly superior to the other?

    Head-to-head randomized controlled trials comparing lurasidone and quetiapine specifically for bipolar depression are relatively limited. However, both medications have established evidence in treating bipolar depression, with some distinctions in efficacy, safety, and tolerability that can be informative for comparison.

    1. Efficacy: Studies suggest that both lurasidone and quetiapine are effective in treating depressive symptoms in bipolar disorder. Quetiapine, particularly at doses of 300 mg or 600 mg, has shown significant efficacy in reducing depressive symptoms, whereas lurasidone also demonstrates effectiveness at doses typically ranging from 20 mg to 120 mg. Head-to-head trials generally find comparable efficacy between the two, though quetiapine may be preferred in certain cases for its sedative effects, which can help with associated insomnia in bipolar depression.
    2. Tolerability and Side Effects: Lurasidone tends to have a more favorable side effect profile, with a lower risk of weight gain, metabolic issues, and sedation compared to quetiapine. Quetiapine is often associated with more sedation and metabolic side effects, such as weight gain and increased cholesterol and triglycerides, which may be more pronounced at higher doses. Lurasidone’s side effect profile may make it a better option for patients where weight gain or sedation is a concern.
    3. Functioning and Quality of Life: Some studies highlight that patients on lurasidone report better functioning and fewer sedative effects, which may positively impact quality of life, particularly for those sensitive to the sedative properties of quetiapine.
    4. Dropout Rates: Due to quetiapine’s sedative side effects, some patients discontinue it more often than lurasidone. Lurasidone’s lower risk for sedation and weight gain tends to improve adherence for those struggling with quetiapine’s tolerability.

    Both medications are effective for bipolar depression, but lurasidone may be better tolerated overall, especially concerning weight gain and sedation. We should not forget that lurasidone carriers an equally concerning side effect of akathisia which can also increase dropout rates especially at higher doses. Additional direct head-to-head trials would be valuable to further elucidate these findings.

  • Unlocking Relief: Can Prazosin Power Up Depression Treatment?

    Unlocking Relief: Can Prazosin Power Up Depression Treatment?

    The evidence for the use of prazosin in major depressive disorder (MDD) comes mainly from smaller studies or trials focusing on its off-label use, as prazosin is primarily an alpha-1 adrenergic antagonist used to treat hypertension and PTSD-related nightmares.

    Clinical Rationale

    The theoretical rationale for prazosin in MDD is based on its ability to block alpha-1 adrenergic receptors, which may help reduce the hyperactivity of the norepinephrine system—a pathway implicated in stress and depression.

    Randomized Controlled Trials (RCTs)

    RCT evidence for prazosin in treating MDD is limited compared to other antidepressants, but a few studies have explored its potential benefits:

    1. Prazosin as Adjunctive Treatment for MDD (2009):
      A small pilot RCT assessed prazosin as an add-on therapy for MDD in patients who were already on standard antidepressants. The results showed modest improvements in depressive symptoms when prazosin was combined with SSRIs or SNRIs, particularly in patients with high anxiety or sleep disturbances.
    2. Prazosin for PTSD and MDD Comorbidity:
      Some RCTs conducted in patients with PTSD (a condition often comorbid with MDD) showed improvements in both PTSD and depressive symptoms. For example, a trial published in 2015 demonstrated that prazosin led to a significant reduction in depressive symptoms in veterans with PTSD and depression. While the trial primarily focused on PTSD, the secondary outcomes regarding depression were positive.
    3. Prazosin and Treatment-Resistant Depression (TRD):
      Some trials have explored prazosin’s efficacy in treatment-resistant forms of depression, hypothesizing that its ability to reduce stress-related symptoms could augment antidepressant efficacy. However, these trials have generally been small, and results have been inconsistent or not statistically significant in terms of primary depressive outcomes.

    Limitations

    • Sample Sizes: Most studies are small and underpowered.
    • Population: Most studies have focused on patients with PTSD, rather than pure MDD.
    • Adjunctive Use: Prazosin has mostly been tested as an adjunctive treatment, not as monotherapy for depression.

    While prazosin has shown some promise in improving depressive symptoms, particularly related to sleep disturbances and anxiety, larger RCTs specifically targeting MDD are needed to establish its efficacy.

  • Can Amantadine Tame Tardive Dyskinesia? Exploring the Evidence and Potential Benefits

    Can Amantadine Tame Tardive Dyskinesia? Exploring the Evidence and Potential Benefits

    In my practice, I see many patients who have been on high doses of antipsychotics for extended periods, particularly first-generation antipsychotics, which carry a higher risk of developing tardive dyskinesia (TD). While two FDA-approved treatments for TD exist, their high cost and limited availability can make access challenging in community mental health settings. This has led me to explore alternative treatments like amantadine. Like many of you, I wanted to understand the evidence supporting its use, so let’s take a closer look at what the research says about amantadine as a treatment option for TD.

    The evidence for the use of amantadine in treating tardive dyskinesia (TD) has been explored in several small randomized controlled trials (RCTs), though it remains limited compared to other treatments.

    1. Efficacy of Amantadine: Some studies suggest that amantadine, an NMDA receptor antagonist, may offer mild to moderate improvement in TD symptoms by modulating dopaminergic pathways. For instance, an early RCT (2007) tested amantadine in schizophrenia patients with TD and reported some improvements in abnormal involuntary movements compared to placebo. However, the sample size was small, and results were modest.
    2. Comparative Effectiveness: Few trials directly compare amantadine to other TD treatments like VMAT-2 inhibitors (e.g., valbenazine, deutetrabenazine), which are the preferred treatment options due to stronger RCT evidence. Amantadine’s effects may be less pronounced, though some patients have reported partial symptom relief, especially when TD is not severe.
    3. Safety Profile: In RCTs, amantadine is generally well-tolerated in TD patients, with few serious side effects. However, common side effects include dizziness, insomnia, and gastrointestinal issues, which may limit its use in certain patients, particularly those with cognitive or movement comorbidities.

    Overall, while RCTs support some benefit of amantadine in TD, the effect size is generally moderate. VMAT-2 inhibitors are preferred based on stronger, more consistent RCT data, although amantadine may still be considered for patients who cannot tolerate or do not respond to these primary therapies.

  • The Silent Crisis: Physician Suicide in the United States

    The Silent Crisis: Physician Suicide in the United States

    I saw these magnets today on the refrigerator located in the physicians lounge and it seemed like a good reminder 

    In the U.S., an estimated 300-400 physicians die by suicide each year, a staggering rate far higher than that of the general population. This crisis, largely unspoken in healthcare settings, underscores the immense pressures physicians face daily. The high expectations, long hours, emotional exhaustion, and the stigma around seeking mental health support create a dangerous environment where burnout can quickly spiral into severe mental health struggles.

    Physicians are trained to endure, often putting others’ health before their own. But the costs of “pushing through” take a toll. Many feel they cannot safely reach out for help without risking their careers due to institutional stigma around mental health treatment. This cycle of isolation and suppressed emotion can lead to tragic outcomes.

    Organizations are beginning to address this issue by implementing wellness programs, peer support systems, and confidential mental health resources, but more systemic changes are needed. Reducing the stigma around mental health support, reforming punitive policies, and fostering a culture of openness in medicine could be life-saving.

    Physician suicide affects us all—it robs the healthcare system of dedicated professionals and leaves profound impacts on patients, families, and communities. It’s time to break the silence and actively support those who care for us.

  • Breaking the Cycle: Effective Strategies to Prevent Self-Injurious Behavior (SIB)

    Breaking the Cycle: Effective Strategies to Prevent Self-Injurious Behavior (SIB)

    This post comes from another real-world case that I frequently encounter in clinical practice. Self-injurious behavior (SIB) is common in the inpatient care setting and the strategies to prevent it are mostly behavioral. Many patients and families are also looking for pharmacological options. Here are some of the more common options and recommendations for treating SIB.

    Behavioral Interventions

    1. Functional Behavior Analysis (FBA): Start with an FBA to understand why the self-injury is occurring (e.g., to gain attention, avoid demands, or self-soothe). This guides intervention planning.
    2. Positive Reinforcement and Skill Building: Reinforce alternative, adaptive behaviors that fulfill the same needs as self-injury, such as communication skills (e.g., teaching to request attention) or self-soothing techniques.
    3. Cognitive Behavioral Therapy (CBT): For individuals able to engage in talk therapy, CBT can address underlying thoughts and emotions driving SIB, such as distress intolerance, perfectionism, or negative self-beliefs.
    4. Dialectical Behavior Therapy (DBT): DBT is particularly effective for reducing SIB, especially in borderline personality disorder. It combines emotional regulation, mindfulness, and distress tolerance skills.
    5. Environmental Modifications: Minimizing triggers in the individual’s environment can help reduce occurrences. This might include changes in routines, avoiding overstimulation, or modifying demands.
    6. Applied Behavior Analysis (ABA): Techniques from ABA, like differential reinforcement of other behaviors (DRO) or non-contingent reinforcement (NCR), can reduce self-injury by decreasing its functional value.

    Pharmacological Interventions

    1. SSRIs (Selective Serotonin Reuptake Inhibitors): Useful if self-injury is driven by anxiety, depression, or obsessive-compulsive tendencies. SSRIs can help stabilize mood and reduce anxiety, lessening the need for SIB.
    2. Antipsychotics: Atypical antipsychotics, such as risperidone or aripiprazole, are sometimes effective, particularly in autism spectrum disorders or severe intellectual disabilities. However, weigh these benefits against side effects, especially for long-term use.
    3. Mood Stabilizers: Medications like lithium, lamotrigine, or valproate can help regulate mood fluctuations that contribute to SIB. Lithium, in particular, has shown effectiveness in reducing aggression and impulsivity.
    4. Naltrexone: This opioid antagonist can be effective in cases where SIB is hypothesized to release endogenous opioids, providing a calming effect.
    5. Beta-blockers (e.g., propranolol): In cases of high impulsivity or aggression linked to SIB, beta-blockers can reduce physiological arousal, lessening the drive for self-injury.
    6. Clonidine or Guanfacine: These medications, which target the noradrenergic system, can help reduce impulsivity and aggression in patients with ADHD or autism, indirectly lowering self-injury.

    Choosing the best approach depends on the individual’s specific triggers, co-occurring conditions, and underlying motivations for SIB. Integrating both behavioral and medication interventions, while monitoring closely for effectiveness and side effects, often yields the best outcomes.

  • Brighten Your Mood: Light Therapy to Combat Daylight Savings Blues!

    Brighten Your Mood: Light Therapy to Combat Daylight Savings Blues!

    With daylight savings time quickly approaching a summary of the randomized controlled trial evidence for light therapy in seasonal affective disorder (SAD), particularly in relation to daylight savings time seems appropriate this week. 

    Efficacy of Light Therapy for SAD

    Several randomized controlled trials have demonstrated the efficacy of light therapy for treating seasonal affective disorder:

    A meta-analysis of randomized controlled trials found that bright light treatment was associated with a significant reduction in depression symptom severity in SAD, with an effect size of 0.84 (95% CI: 0.60 to 1.08)

    Another meta-analysis revealed that dawn simulation light therapy was also effective for SAD, with an effect size of 0.73 (95% CI: 0.37 to 1.08)

    One study found that exposure to bright light (10,000 lux) for as little as 20-40 minutes could lead to significant improvements in mood scores in SAD patients

    Timing and Duration of Light Therapy

    Light therapy is typically administered daily for at least several weeks during the fall and winter months

    One study found that 40 minutes of exposure to 10,000 lux light resulted in greater improvement than 20 minutes, but was not significantly different from 60 minutes of exposure

    The rate of mood improvement was steepest during the first 20 minutes of light exposure

    Mechanisms and Considerations

    The efficacy of light therapy is thought to be related to its effects on circadian rhythms and neurotransmitters like serotonin

    Light boxes used for therapy should provide 10,000 lux of light and have screens that filter out UV rays

    Light therapy is generally recommended to be used within the first hour of waking up in the morning

    Limitations of Current Evidence 

    Many studies on light therapy for SAD have not used rigorous study designs

    There is limited research specifically examining the effects of light therapy in relation to daylight savings time changes.

    More long-term follow-up studies are needed to assess the safety and potential side effects of light therapy

    While the evidence supports the efficacy of light therapy for SAD, there is a need for more rigorous, large-scale randomized controlled trials to further establish its effectiveness, optimal timing, and duration, particularly in relation to daylight savings time changes. The current evidence suggests that light therapy can be an effective treatment option for SAD, with effects comparable to antidepressant medications

    Resources: 

    https://psychiatryonline.org/doi/10.1176/appi.ajp.162.4.656

    https://pmc.ncbi.nlm.nih.gov/articles/PMC2913518

    https://www.mayoclinic.org/diseases-conditions/seasonal-affective-disorder/in-depth/seasonal-affective-disorder-treatment/art-20048298

  • ADHD and Cannabis Use Disorder: Key Facts You Shouldn’t Ignore

    ADHD and Cannabis Use Disorder: Key Facts You Shouldn’t Ignore

    1. Prevalence and Patterns of Use

    People with ADHD have been shown to use cannabis at higher rates than those without ADHD. Studies indicate that adolescents and adults with ADHD are more likely to use cannabis, and they may start using it at a younger age. This may be due to self-medication attempts, as people with ADHD often report using cannabis to help with symptoms like impulsivity, anxiety, and sleep difficulties which seems like a bad idea to me but lets look at the reasons.

    2. Cannabis as a Self-Medication Attempt

    Some people with ADHD use cannabis in an attempt to self-manage their symptoms. Anecdotally, users report feeling more focused, relaxed, and less anxious, though the scientific evidence on cannabis’s effectiveness for ADHD symptom management is not robust. Studies show that while some ADHD symptoms like restlessness might feel alleviated short-term, long-term outcomes often do not show sustained benefit, and impairment can increase over time.

    3. Impact on ADHD Symptoms

    Research on cannabis’s effect on ADHD symptoms is mixed:

    • Impulsivity and Attention: Cannabis can impair attention, memory, and executive functioning, which are already areas of struggle for individuals with ADHD. Heavy cannabis use is associated with poorer performance on tasks measuring these cognitive domains.
    • Cognitive Function: Longitudinal studies have shown that chronic cannabis use can worsen cognitive functions over time, especially if use begins in adolescence. These cognitive impacts may compound ADHD-related deficits.
    • Motivation and Goal-Directed Behavior: Cannabis can affect motivation and goal-directed behavior, which can exacerbate some ADHD symptoms, particularly in individuals who already struggle with organization and task completion.

    4. ADHD as a Risk Factor for Cannabis Use Disorder

    Studies suggest that people with ADHD may be more prone to developing cannabis use disorder (CUD) compared to the general population. Traits like impulsivity and sensation-seeking, common in ADHD, may increase vulnerability to addiction. Additionally, the reinforcing effects of cannabis (e.g., reduction in perceived anxiety) may lead to increased use and dependency in those with ADHD.

    5. Genetic and Neurobiological Factors

    There is some evidence suggesting that the overlap between cannabis use and ADHD may have a genetic or neurobiological basis:

    • Genetic Overlap: Studies have found that genes linked to ADHD, particularly those affecting dopamine function, are also implicated in substance use disorders, including cannabis use disorder.
    • Endocannabinoid System: ADHD and cannabis use affect dopamine and endocannabinoid systems. Some research posits that dysregulation in these systems might underlie both the propensity for ADHD and substance use, but this remains an area for further research.

    6. Cannabis and Medication Interactions

    For those with ADHD taking stimulant medications, cannabis use can interfere with treatment. THC, the psychoactive component of cannabis, can interact with medications like methylphenidate or amphetamine-based treatments, potentially reducing their effectiveness or exacerbating side effects like anxiety and heart palpitations.

    7. Longitudinal and Population Studies

    Long-term studies generally show that early and heavy cannabis use is associated with worse outcomes for individuals with ADHD. These include lower academic achievement, increased rates of unemployment, and higher incidences of mental health issues, especially when cannabis use starts in adolescence.

    Summary

    While some people with ADHD report short-term symptom relief with cannabis, research shows that heavy, frequent use tends to worsen cognitive deficits associated with ADHD over time. Additionally, ADHD may predispose individuals to higher rates of cannabis use and a greater risk of developing cannabis use disorder. While cannabis might seem beneficial for symptom relief in the short term, its long-term use is generally not supported as an effective management strategy for ADHD.